

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/258202151>

Interactions of Mesenchymal Stem Cells with Endothelial Cells

Article *in* Stem cells and development · February 2014

DOI: 10.1089/scd.2013.0419 · Source: PubMed

CITATIONS

11

READS

398

2 authors, including:



Reza Rahbarghazi

Tabriz University of Medical Sciences

29 PUBLICATIONS 78 CITATIONS

SEE PROFILE

Interactions of Mesenchymal Stem Cells with Endothelial Cells

Seyed Mahdi Nassiri and Reza Rahbarghazi

Recent years have witnessed the emergence of a considerable amount of data pertaining to the application of bone marrow mesenchymal stem cells (MSCs) in promoting angiogenesis in the field of regenerative medicine. Nevertheless, some authors have provided evidence that MSCs can also prevent the process of angiogenesis, which is desirable in certain pathologies such as tumor growth. Plenty of *in vitro* and *in vivo* research studies have been undertaken to illuminate the underlying mechanisms by which MSCs promote or inhibit neo-angiogenesis. To date, both secretory capacity and differentiation into endothelial-like cells have been reported in MSC-based pro-angiogenic therapies. This review seeks to shed further light on interactions between MSCs and endothelial cells in different physiopathological conditions.

Introduction

AT PRESENT, STEM CELLS and—in particular—bone marrow mesenchymal stem cells (MSCs) are heralded as a source of great promise for augmenting angiogenesis during tissue repair/regeneration [1]. However, over the years, there has been much controversy over the fundamental biology, kinetics, and therapeutic application of MSCs on different kinds of pathological conditions—especially angiogenesis-dependent illnesses. Equivocal research paradigms or inconsistent results have—to some extent—contributed to the ambiguity or uncertainty over the behavior of MSCs in cell-based therapies.

Angiogenesis is defined as the formation of new capillaries from pre-existing vessels and consists of several steps—including stimulation of endothelial cells (ECs), extracellular matrix (ECM) degradation, migration, and proliferation of ECs, capillary tube formation, and, eventually, stabilization of newly formed tubes by peri-ECs such as pericytes (PCs) [2]. The dynamic balance between pro-angiogenic and anti-angiogenic factors in milieu shifts equilibrium to vessel formation or regression. The great potency of expansion, pro-angiogenic properties, and easy harvesting of MSCs render these cells a good candidate for angiogenesis-augmenting or inhibiting purposes [3,4]. There are a number of preclinical and pioneering clinical studies corroborating that MSCs can differentiate into endothelial-like cells, vascular smooth muscle cells, and PCs.

MSCs have been administrated intravenously and shown to have distributed among several tissues in animal models. Similar to leukocytes and progenitor cells, MSCs also coordinate the sequence of adhesion steps (cytoskeletal and motogenic changes) to egress from blood stream [5,6].

Moreover, a variety of pro-angiogenic factors have been elucidated in MSC secretome, which facilitate the proliferation and migration of ECs and contribute to the recruitment of endothelial progenitor cells (EPCs) into newly sprouting blood vessels [1,7–12]. In contrast, novel properties of MSCs, as anti-angiogenic/cytotoxic agents that abrogate capillary formation, have also been observed in some experiments and tumors which are thought to mediate via cell-cell contact or paracrine signaling [13,14]. Appreciable efforts have been undertaken to illuminate the mechanisms underlying the interaction between MSCs and ECs or peri-ECs in both *in vivo* and *in vitro* experiments.

This review aims at scrutinizing the interaction between MSCs and ECs or peri-ECs during neo-angiogenesis, tumor vascularization, and vascular remodeling.

Trans-Endothelial Migration of MSCs

MSC adhesion

It was demonstrated that MSCs could adhere to the endothelium and extravasate at the site of inflammation by a leukocyte-like, novel mechanism controlled by a precisely regulated interaction between stem cell and endothelium via selectin-mediated rolling, chemokine-triggered activation, and integrin-dependent arrest on the endothelium (Fig. 1) [15,16].

It was clearly demonstrated that MSCs have the extensive ability to influence the behavior of ECs and vice versa, especially via ligand–receptor interactions (Fig. 1) [17,18]. The migration and homing potential of MSCs to sites of injury as well as MSC-EC adhesion was shown to be governed by a




FIG. 1. This schematic illustration summarizes the stages for the recruitment and contribution of bone marrow MSCs to target tissues. Chemoattractants, released by target tissues, circulate to reach the marrow-resident MSC niche. Next, factor-activated MSCs leave the bone marrow and enter into the blood stream. Under shear flow and in the blood vessels of target tissues, MSCs are tethered by endothelial cells (ECs) and then, they start rolling on the EC-lined surface. As shown, selectins are the first adhesion molecules that mediate cell-to-cell contact. MSCs have the capability to express L-selectin, whereas ECs express P- and E-selectins on the luminal surface. Simultaneously, other adhesion or synergetic molecules are expressed on the cell membrane of MSCs (VLA-1, CD44, and LFA-1) and ECs (ICAM-1, VCAM-1, vWF, CD44, and S-Lex). Then, the attached stem cells firmly adhere to the endothelial surface through the binding of β -integrins on the MSC membrane with their receptors (VCAM-1 and ICAM-1) on ECs. It is also believed that released chemokines determine tropism to target tissues. In addition, MSCs are able to express chemokine receptors, that is, CXCR₃, CXCR₆, CCR₆, and CCR₉. There are two modes of trans-migration for MSC extravasation—including para- (inter-endothelial space migration) and trans-migration (through EC). Receptor ligands are essential for the trans-endothelial migration of MSCs. CD31 (PECAM-1), cadherins, and JAMs molecules are also exploited in this stage. Moreover, the secretory potential of MSCs facilitates extra-vascular movement. For example, secreted MMP-2 degrades endothelial basal membrane. ECs-derived MMP-9 and nitric oxide also play a role in this phenomenon. ECs, endothelial cells; ICAM-1, intercellular adhesion molecule-1; JAMs, junctional adhesion molecules; LFA-1, leukocyte function-associated antigen-1; MMP-2, -9, matrix metalloproteinase-2, -9; MSCs, mesenchymal stem cells; PECAM-1/CD31, platelet endothelial cell adhesion molecule, S-Lex, Sialyl Lewis x; VCAM-1, vascular cell adhesion molecule-1; VLA-4, very late antigen-4; vWF, von Willebrand factor.

vast array of different cell surface trans-membrane molecules such as integrins [19]. Integrins, as eukaryotic cell surface receptors, consist of heterodimers of α (α_1 to α_8) and β (β_1 to β_{16}) subunits. Each subunit contains a large extracellular and a small cytoplasmic domain [20]. MSCs, similar to other cells, express subunits β (β_1 to β_3) and α (α_1 to α_6 , and α_V) in the cell culture system. On reaching confluency, the expression

of β_3 , α_1 , α_3 , α_5 , and α_V integrins is increased, whereas the expression of α_6 is decreased. Specific integrins play a role in the adhesion of MSCs to a variety of human ECs such as pulmonary arteries (β_1 , α_V , and α_X), cardiac-derived microvasculature (β_2 , α_X , α_7 , and α_D), and umbilical veins (β_1 , β_2 , and β_3); whereas the neutralizing antibodies against the integrins of the β_5 subclass reduce MSC adherence to all the

ECs mentioned earlier [19]. Integrin-dependent intracellular signaling is believed to be induced in leukemic cells in the MSC-leukemic cell co-culture system, which is mediated by integrin-linked kinase (ILK) that phosphorylates protein kinase B (Akt) in a phosphatidylinositol 3-kinase (PI3K)-dependent manner [21]. It was shown that the expression of VEGF in tumor cells was stimulated by ILK via stimulating HIF-1 α expression, and inhibition of ILK expression or activity resulted in the inhibition of VEGF-mediated EC migration, capillary formation in vitro, and angiogenesis in vivo [22] and suppressed VEGF-induced p38 mitogen-activated protein kinase (MAPK) and Akt phosphorylation in ECs [23]; so, the integrin-dependent interaction between MSCs with ECs may trigger neo-angiogenesis in ECs.

Notch receptors, Notch-1 to 4, with five structurally similar ligands—namely Delta-like1, Delta-like3, Delta-like4 (Dll-1 to 4), Jagged-1, and Jagged-2—are other types of counter receptors that provoke MSC-EC interaction [24]. Notch-1, -2, and -3 receptors and Jagged 1 ligand were shown to be expressed at significant levels in MSCs [24]. Notch-1 was found to increase the proliferation as well as recruitment of MSCs (more Ki-67⁺ proliferative and less cleaved-Caspase3⁺ apoptotic cells) to the infarcted murine myocardium [25]. Chiming with these observations, the activation of MSCs via TNF- α and Interleukin-1 treatment before the injection significantly enhanced adhesion to the cardiac endothelium and promoted the homing of MSCs via ICAM-1/LFA-1 and G-protein-coupled receptor signaling [15,26,27]. Ruster and colleagues demonstrated that MSCs underwent coordinated rolling on and adhesion behavior to ECs under shear flow and reported that human MSCs did not express detectable levels of some adhesion molecules such as P-selectin glycoprotein ligand 1 (PSGL-1) and preincubation of MSCs—with the antibody against PSGL-1—did not block the binding of MSCs to the surface of ECs (Fig. 1) [5]. Meanwhile, preincubation of HUVECs with a blocking antibody against P-selectin strongly decreased MSC binding to EC, indicating that MSCs might bind to P-selectin using a fucose and sialic acid-containing ligand that is different from PSGL-1 [5]. In addition, the preincubation of ECs with anti-VCAM-1 or of MSCs with anti-VLA-4 prevented the adhesion of MSCs to ECs (Fig. 1). Finally, the authors concluded that MSCs bound to ECs in a P-selectin-dependent manner either in vitro or in vivo, and that CD44 as well as VLA-4/VCAM-1 was engaged in the rolling of MSCs on ECs [5,28].

An increase in the level of cell surface CD44 by the platelet-derived growth factor (PDGF) stimulation of MSCs facilitated cell migration through an interaction with extracellular hyaluronic acid (Fig. 1) [29]. In addition, P- or L-selectin aptamers-engineered MSCs efficiently adhered on the respective selectin surfaces of ECs and leukocytes [30]. Sackstein et al. reported that a CD44 glycoform—bearing α -2, 3-sialyl modifications—was expressed on human MSCs but they lacked E-selectin ligands and CXCR4, which limited osteo-tropism to the bone tissue. Therefore, the modification of native CD44 to convert it into E-selectin/L-selectin ligand conferred potent binding capacity and tropism to the bone tissue through specialized marrow vessels expressing E-selectin [31].

Potapova et al. demonstrated that the treatment of ECs with the von Willebrand factor (vWF) resulted in the activation of intracellular downstream ERK-1, 2, and p38 MAPK

without an effect on the gene or cell surface expression of E-selectin, P-selectin, VCAM1, and ICAM1. They showed that the activation of p38 MAPK in ECs by the vWF could initiate MSC-EC adhesion (Fig. 1) [32]. Nevertheless, VCAM-1/VLA-4 as well as beta 1 integrins and matrix metalloproteinase 2 play key roles in the trans-endothelial migration of MSCs [33]. The addition of MSCs to ECs tubes on the Matrigel assay initiated MSC-EC intercalation via connexin 43-based intercellular gap junction [13]. Some MSC-derived secretory soluble factors could up-regulate connexin-43 and facilitate the functional integration of MSCs into target tissues [34].

Trans-endothelial migration

The firm adhesion of MSCs to ECs is followed by endothelial transmigration via platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31), junctional adhesion molecules (JAMs), and cadherins (Fig. 1) [15,35,36].

Similar to leukocytes, MSCs transmigrate by para- (between ECs) and trans-cellular (directly through individual ECs) diapedesis through discrete pores and gaps in the endothelial monolayer—which is associated with VCAM-1-enriched trans-migratory cups [15]. Both lamellipodia (a flattened cellular extension over surface) and invadosomes (a dot-like accumulation of the filamentous actin at the site of cell-matrix contact) [37] were observed in the trans-migratory process of MSCs; however, unlike leukocytes, nonapoptotic membrane blebbing was also evident, as was previously described for metastatic tumors [15].

Chemokine receptors are known as G-protein-coupled receptors for CXC, CC, C, or CX3C chemokines. MSCs express CCR1, CCR2, CCR4, CCR6, CCR7, CCR9, CCR10, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, and CX3CR1 receptors and secrete a variety of chemokines [38,39]. Chamberlain et al. stated that chemokine receptors and their chemokine ligands had an indispensable role in the migration of murine MSCs (mMSCs) across murine aortic endothelial cells (MAECs) and that both chemokine stimulation and shear stress enhanced the trans-endothelial migration of mMSCs across MAECs [28]. Initially, mMSCs established fine microvillous processes, namely filopodia, and then extended pseudopodia in multiple directions. Thereafter—CXCL9, CXCL16, CCL20, and CCL25 ligands improved trans-endothelial migration across MAECs, and shear forces markedly stimulated the crawling and spreading of mMSCs [28].

In addition to the direct MSC-EC cross-talk via receptor/ligand interactions, ECM also regulates MSCs migration during vascular remodeling (Fig. 1). MSC binding to matrix fibronectin induced the α 5 β 1-integrin-dependent phosphorylation of PDGFR- β , leading to PI3K/Akt activity, actin re-organization, and MSCs migration [6]. However, in spite of the effective role of the ECs on the extravasations of MSCs, MSCs—in turn—could contribute to the growth of ECs into the EC-MSC islets by paving the way via producing proteases into the tissue [40]. During myocardial infarction and in inflammatory conditions, endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) production, by PI3K/Akt/eNOS downstream signaling and MMP-9 activation, could trigger MSCs and EPCs migration to target tissues [41].

MSC-EC Cross-Talk in Angiogenesis

Various types of MSC-EC three-dimensional (3D) co-culture systems have revealed extensive cellular cross-talk through a variety of mechanisms. This process is exquisitely controlled by cell-cell connection, paracrine, and juxtacrine interaction—or vesicle trafficking between the MSC and EC lineage, leading to the modulation of the angiogenic response (Fig. 2A) [1,42].

Juxtacrine interactions of MSC-EC

In an in vitro Matrigel assay using rat and human MSC-EC co-culture systems, self-assembled and elongated tube-like structures are formed by intimate MSC-EC contact soon after seeding on Matrigel, and, subsequently, EC phenotype is induced in co-aligned MSCs via VEGF-dependent downstream signaling and then activation of the Rho/ROCK pathway [1,43]. MSCs that express stemness markers such as




FIG. 2. This schematic illustration presents the potential effects of MSCs on ECs in angiogenesis. **(A)** MSCs interact with ECs in three different manners: paracrine; juxtacrine; and vesicle trafficking. A different panel of angiogenic growth factors, cytokines, and other signaling molecules are secreted by MSCs, which may influence ECs. MSC-derived factors are to promote the angiogenesis process after binding to the relevant receptors on the EC surface. Moreover, the intercellular trafficking of exosomes transfers various kinds of molecules—including proteins, mRNAs, microRNAs, and lipid molecules to target cells. Finally, juxtacrine interactions require cell-to-cell physical contact through ligand-receptor interactions. All these mechanisms, ultimately, induce or inhibit different intracellular signaling pathways, which, in turn, lead to the promotion of angiogenesis. **(B)** The endothelial differentiation of MSCs involves concomitant changes in the expression of EC-specific genes—including *KDR*, *FLT-1*, *vWF*, *VEGFR-1*, and *VEGFR-2*. VEGF, the most prominent EC-inductive phenotype in MSCs, acts via Rho/ROCK and MRTF-A signaling, leading to the up-regulation of *CYR61/CNN-1* gene. In addition, extracellular mechanical properties influence the trans-differentiation of MSCs through an interaction between ECM proteins and MSC surface receptors, thereby inducing mechano-transduction signaling pathways in MSCs. Also ECs, by themselves, initiate MSC differentiation into endothelial-like cells by producing NO. Ang-1/Tie-2, angiopoietin 1/Tie-2; bFGF, basic fibroblast growth factor; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; FLT-1, Fms-related tyrosine kinase-1 (VEGFR-1); HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor-1; IL-1 β , -10, Interleukin-1 β , -10; KDR, kinase insert domain receptor (VEGFR-2); MCP-1, monocyte chemoattractant protein-1; MIP-1 α / β , macrophage inflammatory protein-1 alpha/beta; MRTF-A, myocardin-related transcription factor-A; PDGF, platelet-derived growth factor; PDGFR β , platelet-derived growth factor receptor beta; PLAUR, plasminogen activator urokinase receptor; SDF-1 α , stem cell-derived factor-1 α ; VEGF, vascular endothelial growth factor; VEGFR-2, vascular endothelial growth factor receptor-2.

CD146, Sca-1, and PDGFR α have been shown in close proximity of vessels with a tendency to express PCs-like markers, NG2, CD146, and PDGFR β . As a matter of fact, it has recently been demonstrated that CD146⁺ PCs represent a subpopulation of bone marrow MSCs which support neo-angiogenesis [44]. PDGFR α ⁺ progenitor cells also have a great potential to mimic endothelial as well as smooth muscle cell phenotypes in the heart [45]. In vivo perivascular homing of MSCs along the vascular wall was also observed after an IV injection of MSCs in a critically ischemic murine skin flap model [46]. In addition, in vivo co-implantation of MSCs isolated from four murine tissues, including bone marrow, white adipose tissue, skeletal muscle, and myocardium, with human blood-derived endothelial colony-forming cells developed a complex network of blood vessels with ECs lining the lumens and MSCs aligning the perivascular space immediately adjacent to the luminal structures [47]. Indeed, the existence of MSCs in the peri-endothelial space highlights the notion that endothelium, as an important component of MSC niche, can regulate the functional activity of MSCs [48–50].

MSCs-derived spindle-shaped myofibroblast-like cells, containing organized smooth muscle alpha-actin filaments, were also determined in the EC-MSC co-culture [51]. With regard to intracellular signaling, HUVECs, in a 3D spheroid co-culture system, promoted endogenous Wnt as well as BMP signaling in human MSCs with an increased level of nuclear β -catenin and pSmad1/5/8 under osteogenic conditions [52]. The MSC-EC interaction enhances the expression and co-localization of VE-cadherin and β -catenin at the cell membrane, decreases vascular tube breakdown, and inhibits ECs permeability with the preservation of VE-cadherin, Claudin-1, and Occludin-1 in vivo in the pulmonary ECs in a rat model of hemorrhagic shock-induced acute lung injury [53] and in vitro in a human MSC-EC co-culture system [54,55]. Secreted frizzled-related protein-1 (sFRP-1), as the soluble modulator of Wnt signaling, up-regulated PDGF-BB in mMSCs and facilitated β -catenin-dependent MSC-MSC, MSC-EC, and MSC-SMC adhesions in vitro [56]. This pathway, in turn, triggered MSC glycogen synthase kinase 3 beta (GSK3 β)-dependent angiogenesis as well as vessel maturation and functionality after a subcutaneous injection of MSCs mixed with Matrigel in mice, although no endothelial differentiation of MSCs was evident by this pathway [56,57]. Other studies implicated sFRP-2 as a key molecule for the regenerative potential of mMSCs after transplantation into myocardial infarction [58]. Specific knockdown of sFRP-2 in mMSCs decreased the MSC engraftment and vascular density in the granulation tissue [58].

The proliferation rate of rat MSCs was reportedly reduced in the EC-MSC co-culture, which is in consequence of the down-regulation of a number of growth factors—especially TGF- β family members [1,42]. Duffy and colleagues, however, showed that human MSCs increased aortic ECs proliferation in a noncontact co-culture system using human cells [59]. Bidarra et al. reported that human MSC-EC coculturing not only augmented the proliferation of MSCs but also triggered osteogenic differentiation by ECs-dependent BMP-2 signaling [60]. These authors used three ratios of MSC-EC, including 3:1, 1:1, and 1:3 ratios, and found that the relative number of ECs declined over time in all cell ratios with the most tremendous downward trend in the highest

percentage of MSC to EC ratio. Moreover, the maximum metabolic activity of MSCs was achieved at 1:1 MSC to EC ratio. They also showed that a combined medium of M199 + DMEM provided optimal outcome on the metabolic activity and protein content of MSC compared with M199 or DMEM alone. On the other hand, when rat-derived MSCs were added to rat lung microvascular EC-derived capillaries in Matrigel at EC-MSC ratios of 1:1 or 3:1, degeneration of the capillaries was notified as a result of reactive oxygen species production by MSCs [13]. Such discrepancies seem to be partly related to culture conditions and difference in the origin of the cells employed in each of these in vitro systems. [60]. The addition of human MSCs at an increasing dose from 1:10 to 1:1 MSC-EC ratio to pre-established human aortic EC lattice at Matrigel surface after 24 h proportionally increased the thickness of vessel-like structures and junction size, whereas the addition of MSCs before EC seeding on Matrigel resulted in only EC bunching and loss of lattice formation [59]. Therefore, it seems that the addition of MSCs to the EC-derived fully formed lattice contributed, similar to PCs, to the stabilization and maturation of the vessel-like structures; whereas MSCs acted as a stimulus of EC migration and bunching at early time points during vessel formation [59,61].

Overall, it seems that the inhibitory or stimulatory effect of MSCs on co-cultured ECs is dependent not only on the MSC-EC ratio but also on the sequence of cell addition in different experiments. Since distinct signaling mechanisms can change cell-cell ratios, for example, a change in the intrathymic CD4:CD8 cell ratio from the fetal to adult thymus as a result of differential expression of Notch signaling molecules by the thymic stroma during thymus development [62], it seems that a change in cell-cell ratios might also induce distinct signaling mechanisms with different phenotypic and genotypic profiles.

MSCs also enhanced angiogenesis and vascular integrity by increased angiopoietin-1 (Ang1), Tie2 (Ang-1 receptor), VEGF/VEGFR2 (Flk1), and Occludin expressions in the murine experimental stroke [63]. Ang1/Tie-2 signaling protects MSCs, ECs, and some other cells against insulting conditions such as serum deprivation and hypoxia-induced apoptosis by Akt phosphorylation, increased Bcl-2:Bax ratio, and decreased activation of caspase-9 and -3 [64].

Paracrine interactions of MSC-EC

In addition to the physical contribution of MSCs to the microenvironment, MSCs dynamically influence the surrounding environment through the production of bio-molecules (cytokines, chemokines, growth factors, and ECM molecules) in a paracrine or even autocrine manner. Of these bio-molecules, a variety of angiogenic, immunosuppressive, anti-inflammatory, and anti-fibrotic factors—along with ECM homeostasis regulators such as collagens and tissue inhibitors of MMPs—were delineated [65].

Lipid vesicles of MSCs, including micro- and nano-vesicles, contain the molecules mentioned earlier (Fig. 2A) [66]. Exosome, which is a nano-sized vesicle, serves to transfer various kinds of molecules—including proteins, mRNAs, microRNAs, and lipid molecules. The therapeutic effects of MSC-derived exosomes in cancer therapy or in regenerative medicine such as cardiovascular regeneration have been

investigated by some authors, while our information on the role of exosomes in pathophysiological processes is still in its infancy. There are some pro-angiogenic properties pertaining to MSC exosomes [67]. A number of surface proteins such as PDGFRB, EGFR, and PLAUR, some signaling molecules such as RAS-MAPK, RHO, Cdc42 cell adhesion molecules, osteo-inductive factors, and additional MSC antigens were also determined to be carried out by exosomes [68,69]. Indeed, MSC-derived exosomes have provided a fascinating insight into developing novel cell-free therapeutic approaches that may bypass the difficulties associated with stem cell therapy. The beneficial effects of MSC exosomes have been shown in various diseases, such as stroke [70,71], ischemic heart disease [72], acute lung injury [73], liver fibrosis [74], rheumatic diseases [75], and a number of malignancies, including glioma [76] and multiple myeloma [77].

Moreover, a variety of soluble factors—including VEGF, VEGFR2, Ang-1/Tie2, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 α (MIP-1 α), MIP-1 β , monokine, basic fibroblast growth factor (bFGF), PDGF, IL-1 β , IL-10, stem cell-derived factor (SDF)-1, hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), thymosin- β 4, and Wnt5a—were found to be secreted by MSCs to the conditioned medium (Fig. 2A) [1,65]. MSC-derived VEGF support the survival and functional commitment of ECs [78]. Meanwhile, it has been suggested that at the site of injury when a complex of factors is secreted by multiple stem cells, local angiogenesis might be better stimulated [79]. The soluble fragment of Tie-2, produced by proteolytic cleavage [80], has been detected in the rat MSC conditioned medium—which might participate in the angiogenic axis [1].

The suppression of Wnt-4 expression in hypoxic preconditioned mMSCs abrogated vasculogenic properties in the mouse ischemic hind limb model [81], suggesting that Wnt signaling pathway plays a key role in the paracrine pro-angiogenic properties of MSCs. Moreover, the over-expression of Wnt-4 may enhance the osteogenic differentiation of human MSCs by the activation of p38 MAPK in a novel, noncanonical signaling pathway [82].

Mechanical signals such as compressive loading could also alter the gene expression and function of MSCs. These stimuli are transduced by stretch-activated ion channels, cell adhesion molecules, G-protein-coupled receptors, and growth factor receptor tyrosine kinases [83]. Mechanical loading in a bioreactor system for modeling the fracture gap during the early phase of bone healing induced the up-regulation of pro-angiogenic molecules such as FGF receptor, VEGFR, TGF- β , MMP-2, MMP-9, bFGF, and Membrane Type 1-Metalloprotease (MT1-MMP or MMP-14) in human MSCs [83,84]. Taken together, it is thought that milieu-dependent conditions—including cell-cell contact, soluble factors, and mechanical stimulations—ultimately determine the behavior of MSCs.

Endothelial Differentiation of MSCs

MSCs have the potential for trans-differentiation into endothelial-like cells in both in vivo and in vitro systems [7,85,86]. Nevertheless, the precise mode of action of a wide variety of stimulatory or inhibitory factors such as intracel-

lular signaling molecules, receptors, soluble factors, and even extracellular nanomechanical cues with a considerable influence on endothelial differentiation of MSCs is still under investigation [87,88]. Given the vital importance of neo-angiogenesis in regenerative medicine and the therapeutic potential of MSCs as a promising source of restoring damaged tissue, recent efforts have been focused on employing MSCs both as a source of cells for the regeneration of injured tissues and—at the same time—as a source of ECs [89,90]. There are, however, some controversies among researchers regarding the differentiation of MSCs into ECs—with culture conditions, milieu of targeted tissues, and particular sub-populations of MSCs having been suggested as the potential effectors that regulate the fate of MSCs [87].

Differentiation of MSCs into endothelial-like cells resulted in the expression of a panel of EC-specific markers—including kinase insert domain receptor (KDR), Fms-related tyrosine kinase-1 (FLT-1), and vWF—at both gene and protein levels, which was followed by integrin modulation (Fig. 2B) [7,91,92]. On the contrary, endothelial differentiation induction of human amnion-derived MSCs resulted in the appearance of cells with some angiogenic properties, but a complete differentiation into mature ECs was not achieved because of the down-regulation of pro-angiogenic factors such as tenascin C, Tie-2, VEGF, and FGF2 and up-regulation of anti-angiogenic factors, serpinF1, sprouty1, angioarrestin, and endostatin [90]. Some specific experimental conditions, for example, hypoxic or osteogenesis-inducing conditions, may cause MSCs to secrete the pro-angiogenic factor VEGF and express the endothelial marker VEGFR1 (FLT-1) [93]. Moreover, the capability of MSCs to express the EC-related markers after injection to damaged tissues has been shown by some investigations [94,95].

In addition to the juxtacrine and paracrine mechanisms behind the endothelial differentiation of MSCs, extracellular mechanical properties (as alternative differentiation inducers) influence cell fate at both genotypic and phenotypic levels. For instance, the endothelial differentiation of MSCs was guided through the contact of ECM proteins with MSC surface receptors, resulting in the induction of intracellular mechano-transduction pathways [87,96]. Mechano-sensors and mechano-transduction signaling pathways were also reported to ally MSC fate to the endothelial phenotype under shear stress [97].

VEGF stimulates the differentiation of human and rat MSCs into endothelial-like cells via Rho/myocardin-related transcription factor-A (MRTF-A) family (Fig. 2B) [43]. Further investigations revealed that the activation of the Rho/ROCK signaling pathway promoted the nuclear translocation of MRTF-A [43]. Wang et al. showed that the depletion of MRTF-A selectively ablated the VEGF-induced differentiation of MSCs into endothelial-like cells [43]. In addition, the authors demonstrated that VEGF could up-regulate the promoter activity of *CYR61/CCN1* (regulator of vascular development and angiogenesis) and that MRTF-A knockdown resulted in the reduction of the VEGF-induced activation of *CYR61/CCN1* promoter (Fig. 2B) [43]. Unlike these findings, Au and co-workers concluded that the up-regulation of the myocardin transcription factor promoted MSC differentiation into smooth muscle cells, but instead hampered the differentiation of human MSCs into other lineages—peculiarly ECs [98,99].

The effect of NO signaling in the endothelial differentiation and maturation of EPCs is well documented (Fig. 2B) [100,101]. Moreover, there is some convincing evidence that NO signaling plays a role in the differentiation of MSCs to ECs, although the exact mechanisms underlying the pro-angiogenic effects of NO remain to be clarified [102]. Gomes and colleagues demonstrated that the homozygous ablation of S-nitrosoglutathione reductase (*GSNOR*^{-/-}), a denitrosylase that regulates S-nitrosylation in mice MSCs, profoundly blunted the capacity for vasculogenesis in an in vitro Matrigel tube-forming assay as well as in an in vivo Matrigel plug assay in immunocompromised mice, which was related to NO/GSNOR imbalance [102]. Ahmed et al. showed that the re-programming of rat MSCs with sonic hedgehog, a morphogen during the embryonic development of MSC growth, improved the viability and angiogenic properties of these cells in hearts subjected to myocardial infarction via inducible NO synthase/netrin-1/PKC signaling [103]. In addition to the NO-mediated angiogenic potential of MSCs, NO could also provide osteogenic differentiation in physically activated rat marrow MSCs in vitro [104]. In addition, NO and prostaglandin E₂ released by mechanically stimulated MSCs stimulated osteogenic differentiation in vivo [105]. Moreover, prostaglandin E₂ secretion by implanted MSCs in mice induced a phenotypic switch in macrophages from pro-inflammatory to anti-inflammatory status, and the subsequent recruitment of EPCs and osteogenesis-promoting cells [106].

Ephrin-B2, a trans-membrane ligand for Eph receptor tyrosine kinases, also induced early EC-like phenotype in human MSCs and led to the up-regulation of vWF and VEGFR-2 (KDR/Flk-1) in MSCs under EC culture conditions (Fig. 2B) [59]. On the other hand, Notch signaling was reported to induce the expression of smooth muscle cell markers in human MSCs and embryonic stem cells along with a decrease of endothelial markers in embryonic stem cells [107]. Moreover, in vitro oxidative stress was shown to promote the cardiogenic differentiation of rat MSCs through the activation of Notch-1 signaling [108].

Role of MSCs in Tumor Angiogenesis

It is unanimously agreed that angiogenesis, as a crucial process, is employed in tumor progression and metastasis [109]. The effect of MSCs on tumor growth and angiogenesis has currently generated strong controversy [110]. Indeed, while some evidence indicates a tumor-suppressive effect, there is evidence implying a tumor-promoting effect—especially via vasculature remodeling (Fig. 3) [111]. Tumor-derived vessels usually have a distinct structure and function. Not supported by PCs, tumor-derived vessels are paved by actively dividing ECs, which are irregularly dispersed in the tumor stroma, generating an irregular structure [112]. Despite the distinct nature of the tumor-derived vessels, VEGF signaling also plays a key role in tumor angiogenesis [113,114]. Bidirectional cross-talk interactions and paracrine signaling may contribute to the recruitment of a variety of cells—including progenitor cells and MSCs—into the tumor stroma, which is important for blood vessel formation (Fig. 3) [115,116]. There is strong evidence that tumor development is associated with the continuous recruitment of MSCs, with a tendency to maintain the MSC population at a steady-state level within the tumor mass [117]. Therefore, many

attempts have been made to exploit the tendency of MSCs to tumors, as a tumor-targeting strategy. For example, MSCs are widely used as the delivery vehicles for the transfer of gene constructs in cancer gene therapy [118].

Stimulatory effects of MSCs on tumor angiogenesis

The treatment of MSCs with tumor-derived conditioned media in vitro or close proximity of these cells to tumor microenvironments in vivo resulted in the up-regulation of a number of transcripts—including SDF-1 α (CXCL-12), VEGF-A, PDGF/PDGFR, MIP-2, TGF- β , IL-6, HIF-1 α , NF-K β , bFGF, HGF, angiopoietins, epithelial growth factor, keratinocyte growth factor, IGF-1, and galectin-1 in MSCs—which stimulated tumor neo-angiogenesis (Fig. 3) [10,116,117,119–123]. MSC-derived angiogenic factors induce the proliferation and survival of ECs and smooth muscle cells [124]. Huang and colleagues showed that IL-6 secretion by MSCs, subsequently, promoted endothelin-1 expression in human colorectal cancer cells and triggered Akt and ERK signaling pathways in the neighboring ECs, resulting in the positive tropism of these ECs to the tumor matrix [118]. The co-administration of MSCs and cancerous cells in nude immunocompromised mice resulted in the generation of a highly vascularized tumor mass with the differentiation of MSCs into CD31-positive cells and localization at the sites of active tumor neo-angiogenesis [125,126]. A co-injection of B16 melanoma cells or Lewis lung carcinoma cells and MSCs into syngeneic mice led to increased tumor size with increased tumor vessel area compared with an injection of cancer cells alone [127]. Increased blood vessel area in tumors outgrown from a co-injection of tumor cells with marrow MSCs decreased central tumor necrosis and increased tumor cell proliferation [120]. Localizing close to vascular walls and expressing an endothelial marker by MSCs was proposed as the underlying mechanism behind the supportive effects of MSCs on the tumor vasculature [127]. In C26 colon cancer-bearing mice, inflammatory cytokines such as IFN- γ and TNF- α in the tumor microenvironment could also stimulate MSCs to increase the expression of VEGF via activation of the HIF-1 α signaling pathway, thereby augmenting tumor angiogenesis and accelerating the growth of colon cancer in the animals [128].

Recent findings revealed that MSC exosome-mediated cell-cell interactions contributed to VEGF expression in human tumor cells by activating ERK1/2 pathway [129,130]. It is becoming increasingly clear that cancer-associated fibroblast (CAFs)—which are CD133⁺ and CD44⁺ cells generated from the malignant transformation of MSCs recruited into the tumor stroma—contribute to tumor growth, progression, metastasis, and resistance to chemotherapy in many solid cancers such as brain, breast, and colon cancers (Fig. 3). MSC-derived CAFs are more potent than MSCs to produce cytokines, chemokines, and pro-angiogenic factors [131–134]. Recent evidence also suggested that there was a complex and close bidirectional relationship between MSC-derived CAFs and ECs insofar as ECs-derived cytokines such as NO maintained the stemness-like state of the adjacent CAFs via inducing a Notch pathway in CAFs [135–137]. Reportedly, SDF-1 α produced by MSCs, CAFs, or tumor cells leads to the incorporation of EPCs into the growing tumors, thereby promoting tumor angiogenesis [138]. MSC-derived CAFs can also differentiate to endothelial-like as well as PCs-like cells




FIG. 3. This schematic depiction summarizes the MSC-derived inductive and suppressive mechanisms of tumor angiogenesis. Tumor development is associated with perpetual recruitment of MSCs, with a tendency to maintain the MSC population at a steady-state level within the tumor mass. In addition, MSCs trans-differentiate into cancer-associated fibroblasts (CAFs), which are CD133⁺/CD44⁺. The endothelial differentiation of both MSCs and CAFs could occur in a tumor microenvironment. Although tumor cells promote angiogenesis by the secretion of VEGF and SDF-1 α , CAFs- and MSCs-derived factors also contribute to the induction of angiogenesis and proliferation of ECs as well as recruitment of endothelial progenitors into the tumor mass. In contrast to MSC pro-angiogenic effects, MSCs could inhibit angiogenesis by inducing cell cycle arrest at the G1 phase and apoptosis of ECs, as well as by expressing connexin-43 and producing reactive oxygen species (ROS) with potential effects on ECs. It seems that the balance between the inhibitory and stimulatory effects of MSCs on angiogenesis depends on the tumor niche. EGF, epidermal growth factor; EPCs, endothelial progenitor cells; HIF-1 α , hypoxia-inducible factor 1-alpha; IL-6, interleukin-6; KGF, keratinocyte growth factor; MIP-2, macrophage inflammatory protein-2; NF- κ β , nuclear factor kappa beta; PDGF/PDGFR, platelet-derived growth factor/receptor; ROS, reactive oxygen species; TGF- β , transforming growth factor-beta; VEGF, vascular endothelial growth factor.

and, therefore, stimulate neo-angiogenesis during tumor development (Fig. 3) [139,140]. In a recent study of a KM12SM cell transplantation model of colon cancer, imatinib blockade of PDGFR signaling in CAFs prevented the increase in tumor growth and liver metastasis achieved by co-transplantation of human MSCs and KM12SM human colon cancer cells [141]. Moreover, treatment with imatinib impaired MSCs migration to tumor stroma and decreased the number of MSCs surviving in the tumor microenvironment. Interestingly, new recent studies unveiled that vessels-derived cells might undergo endothelial-to-mesenchymal trans-formation in the context of tumor development—in particular, in hemangioma [142].

Inhibitory effects of MSCs on tumor angiogenesis

Apart from the reported stimulatory effects of MSCs on tumor angiogenesis, there is, however, strong evidence that genetically manipulated or normal MSCs exert inhibitory effects on tumor angiogenesis [143–145]. Many underlying mechanisms are presumed to be responsible for this discrepancy, such as chemokine signaling, modulation of apoptosis, vascular support, and immune modulation (Fig. 3) [144]. Ramasamy and colleagues showed the anti-proliferative activity

of human MSCs on the tumor cells of hematopoietic and nonhematopoietic origin in vitro with transient arrest of tumor cells in the G₁ phase of the cell cycle [145]. A co-injection of tumor cells and MSCs, however, resulted in an increased incidence of tumor growth in immunodeficient mice. Finally, the authors concluded that the discrepancy between the in vitro and in vivo findings would be due to development of a cancer stem cell niche after co-transplantation of MSC in which the tumorigenicity can be augmented [145].

It was demonstrated that some reactive oxygen species are produced when MSCs migrate toward ECs-derived capillaries in Matrigel, which finally led to EC apoptosis. Moreover, an ECs: MSCs ratio-dependent suppression effect on the ECs growth rate was also evident when the cells were co-injected into immunocompromised mice [13]. The mechanistic basis of the inhibitory effects of MSCs on ECs is currently under investigation. For example, human MSCs have the capability to express connexin-43, which mediated gap junctional intercellular communication and functional coupling with ECs [146]. It was shown that MSCs interfere with angiogenesis in a dose-dependent cytotoxicity manner, whereas the administration of an antagonizing peptide against connexin-43 abrogated MSC-derived cytotoxicity behavior [13]. Ho et al. found that co-administration of MSCs

and glioma cells significantly reduced tumor size and vascular density [3]. In MSCs-glioma *in vitro* coculture, they showed reduced expression of PDGF-BB and IL-1 β , and proposed that MSC may exert its antitumor effect through down-regulation of PDGF/PDGFR axis, which is critical for glioma angiogenesis [3]. In fact, tumor cells play a decisive role in mutual cross-talks between the diverse heterogeneity of cell types in the tumor microenvironment [140], suggesting the possibility of dual, contradicting effects of MSCs in tumor neo-angiogenesis. Accordingly, the tumor milieu profoundly influences the interplay between MSCs and ECs.

Conclusion

Since the beneficial effect of MSCs in regenerative medicine was discovered, numerous researchers have sought to understand the potential underlying mechanisms—including proliferation, recruitment, extravasation, homing, and differentiation into the cellular components of damaged tissues. One of the pivotal roles of MSCs is their effect on neo-angiogenesis, which may change the milieu of the targeted tissue. Interactions between MSCs and ECs tend to be quite context dependent, and sometimes completely opposite effects may be seen based on the condition of the target tissue. As a matter of fact, a large number of molecular mechanisms *vis-à-vis* the effect of MSCs on tissue angiogenesis and their interactions with ECs need to be addressed for the optimal application of MSCs in different therapeutic situations. Exposure of marrow-derived MSCs to chemotactic factors triggers a chain of molecular cascades, which promote MSC recruitment toward remote signaling centers. After circulating in the blood stream, MSCs—by expressing adhesion molecules—preferentially mimic inflammatory cell-like mechanisms in their interactions with ECs to transmigrate through the vessel wall. Moreover, recent studies consolidate the notion that MSCs possess juxtacrine and paracrine effects on ECs and are even capable of endothelial trans-differentiation, although the effect of ECs on MSCs should not be overlooked. In addition to the potential properties of MSCs, milieu-dependent conditions define MSC fate as well. It has also been described that MSC-derived chemotactic factors initiate the recruitment of EPCs from the bone marrow, thereby promoting angiogenesis in the target tissue. Investigations through a growing number of studies have revealed both the suppressive and promoting effects of MSCs on tumor growth via vascular remodeling. The contribution of MSCs to tumor niche and bi-directional cross-talks with ECs may affect the tumor response to anti-cancer therapeutics. Endothelial differentiation of MSCs can be induced by various intracellular signaling mechanisms. Meanwhile, controlling MSC function by ECM-mediated elements and mechanical stimulation are other influencing factors that drive MSC differentiation. Taken together, considering the paradoxical effects of MSCs on tissue angiogenesis, it seems that there are intricate mechanisms in cell-to-cell as well as in cell-to-ECM cross-talks, which finally guide stem cell fate and behavior in physiologic and pathologic tissues.

Acknowledgment

This study was supported by a grant from the University of Tehran.

Author Disclosure Statement

No competing financial interests exist.

References

1. Rahbarghazi R, SM Nassiri, P Khazraiiinia, AM Kajbafzadeh, SH Ahmadi, E Mohammadi, M Molazem and M Zamani-Ahmadm Mahmudi. (2013). Juxtacrine and paracrine interactions of rat marrow-derived mesenchymal stem cells, muscle-derived satellite cells, and neonatal cardiomyocytes with endothelial cells in angiogenesis dynamics. *Stem Cells Dev* 22:855–865.
2. Chavakis E and S Dimmeler. (2002). Regulation of endothelial cell survival and apoptosis during angiogenesis. *Arterioscler Thromb Vasc Biol* 22:887–893.
3. Ho IAW, HC Toh, WH Ng, YL Teo, CM Guo, KM Hui and PYP Lam. (2013). Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. *Stem Cells* 31:146–155.
4. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143–147.
5. Ruster B, S Göttig, RJ Ludwig, R Bistrrian, S Müller, E Seifried, J Gille and R Henschler. (2006). Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. *Blood* 108:3938–3944.
6. Veevers-Lowe J, SG Ball, A Shuttleworth and CM Kielty. (2011). Mesenchymal stem cell migration is regulated by fibronectin through $\alpha 5 \beta 1$ -integrin-mediated activation of PDGFR- β and potentiation of growth factor signals. *J Cell Sci* 124:1288–1300.
7. Oswald J, S Boxberger, B Jørgensen, S Feldmann, G Ehninger, M Bornhäuser and C Werner. (2004). Mesenchymal stem cells can be differentiated into endothelial cells *in vitro*. *Stem Cells* 22:377–384.
8. Silva GV, S Litovsky, JAR Assad, ALS Sousa, BJ Martin, D Vela, SC Coulter, J Lin, J Ober, et al. (2005). Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. *Circulation* 111:150–156.
9. Dhar K, G Dhar, M Majumder, I Haque, S Mehta, PJ Van Veldhuizen, SK Banerjee and S Banerjee. (2010). Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. *Mol Cancer* 9:209–221.
10. Chen L, EE Tredget, PYG Wu and Y Wu. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. *PLoS One* 3:e1886.
11. Rafii S and D Lyden. (2003). Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. *Nat Med* 9:702–712.
12. Fathke C, L Wilson, J Hutter, V Kapoor, A Smith, A Hocking and F Isik. (2004). Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. *Stem Cells* 22:812–822.
13. Otsu K, S Das, SD Houser, SK Quadri, S Bhattacharya and J Bhattacharya. (2009). Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. *Blood* 113:4197–4205.
14. Oh JY, MK Kim, MS Shin, HJ Lee, JH Ko, WR Wee and JH Lee. (2008). The anti-inflammatory and anti-angiogenic role

- of mesenchymal stem cells in corneal wound healing following chemical injury. *Stem Cells* 26:1047–1055.
15. Teo GSL, JA Ankrum, R Martinelli, SE Boetto, K Simms, TE Sciuto, AM Dvorak, JM Karp and CV Carman. (2012). Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor- α -activated endothelial cells via both leukocyte-like and novel mechanisms. *Stem Cells* 30:2472–2486.
 16. Ley K, C Laudanna, MI Cybulsky and S Nourshargh. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol* 7:678–689.
 17. Kasper G, N Dankert, J Tuischer, M Hoeft, T Gaber, JD Glaeser, D Zander, M Tschirschmann, M Thompson, G Matziolis and GN Duda. (2007). Mesenchymal stem cells regulate angiogenesis according to their mechanical environment. *Stem Cells* 25:903–910.
 18. Xue Y, Z Xing, S Hellem, K Arvidson and K Mustafa. (2009). Endothelial cells influence the osteogenic potential of bone marrow stromal cells. *Biomed Eng Online* 8:34.
 19. Semon J, L Nagy, C Llamas, HA Tucker, R Lee and D Prockop. (2010). Integrin expression and integrin-mediated adhesion *in vitro* of human multipotent stromal cells (MSCs) to endothelial cells from various blood vessels. *Cell Tissue Res* 341:147–158.
 20. Schneider D and DM Engelman. (2004). Involvement of transmembrane domain interactions in signal transduction by α/β Integrins. *J Biol Chem* 279:9840–9846.
 21. Tabe Y, L Jin, Y Tsutsumi-Ishii, Y Xu, T McQueen, W Priebe, GB Mills, A Ohsaka, I Nagaoka, M Andreeff and M Konopleva. (2007). Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. *Cancer Res* 67:684–694.
 22. Tan C, S Cruet-Hennequart, A Troussard, L Fazli, P Costello, K Sutton, J Wheeler, M Gleave, J Sanghera and S Dedhar. (2004). Regulation of tumor angiogenesis by integrin-linked kinase (ILK). *Cancer Cell* 5:79–90.
 23. Xie W, M Zhao, W Zhou, L Guo, L Huang, W Yu and X Li. (2013). Targeting of integrin-linked kinase with small interfering RNA inhibits VEGF-induced angiogenesis in retinal endothelial cells. *Ophthalmic Res* 49:139–149.
 24. Docheva D, F Haasters and M Schieker. (2008). Mesenchymal stem cells and their cell surface receptors. *Curr Rheumatol Rev* 4:155–160.
 25. Li Y, Y Hiroi and JK Liao. (2010). Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. *Trends Cardiovasc Med* 20:228–231.
 26. Segers VFM, I Van Riet, LJ Andries, K Lemmens, MJ Demolder, AJML De Becker, MM Kockx and GW De Keulenaer. (2006). Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. *Am J Physiol Heart Circ Physiol* 290:H1370–H1377.
 27. Isobe M, H Yagita, K Okumura and A Ihara. (1992). Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. *Science* 255:1125–1127.
 28. Chamberlain G, H Smith, GE Rainer and J Middleton. (2011). Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. *PLoS One* 6:e25663.
 29. Zhu H, N Mitsuhashi, A Klein, LW Barsky, K Weinberg, ML Barr, A Demetriou and GD Wu. (2006). The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. *Stem Cells* 24:928–935.
 30. Zhao W, W Loh, IA Droujinine, W Teo, N Kumar, S Schafer, CH Cui, L Zhang, D Sarkar, R Karnik and JM Karp. (2011). Mimicking the inflammatory cell adhesion cascade by nucleic acid aptamer programmed cell-cell interactions. *FASEB J* 25:3045–3056.
 31. Sackstein R, JS Merzaban, DW Cain, NM Dagia, JA Spencer, CP Lin and R Wohlgemuth. (2008). *Ex vivo* glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. *Nat Med* 14:181–187.
 32. Potapova I, I Cohen and S Doronin. (2010). Von Willebrand factor increases endothelial cell adhesiveness for human mesenchymal stem cells by activating p38 mitogen-activated protein kinase. *Stem Cell Res Ther* 1:35.
 33. Steingart C, F Brenig, L Baumgartner, J Schmidt, A Schmidt and W Bloch. (2008). Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. *J Mol Cell Cardiol* 44:1072–1084.
 34. Haider HK, S Jiang, NM Idris and M Ashraf. (2008). IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1 α /CXCR4 signaling to promote myocardial repair. *Circ Res* 103:1300–1308.
 35. Zhang F, C Wang, H Wang, M Lu, Y Li, H Feng, J Lin, Z Yuan and X Wang. (2013). Ox-LDL promotes migration and adhesion of bone marrow-derived mesenchymal stem cells via regulation of MCP-1 expression. *Mediators Inflamm* 2013:Article ID 691023.
 36. Salem HK and C Thiemeermann. (2010). Mesenchymal stromal cells: current understanding and clinical status. *Stem Cells* 28:585–596.
 37. Linder S. (2009). Invadosomes at a glance. *J Cell Sci* 122:3009–3013.
 38. Ringe J, S Strassburg, K Neumann, M Endres, M Notter, G-R Burmester, C Kaps and M Sittlinger. (2007). Towards *in situ* tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. *J Cell Biochem* 101:135–146.
 39. Smith H, C Whittall, B Weksler and J Middleton. (2011). Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. *Stem Cells Dev* 21:476–486.
 40. Johansson U, I Rasmuson, SP Niclou, N Forslund, L Gustavsson, B Nilsson, O Korsgren and PU Magnusson. (2008). Formation of composite endothelial cell–mesenchymal stem cell islets: a novel approach to promote islet revascularization. *Diabetes* 57:2393–2401.
 41. Li N, X Lu, X Zhao, F-L Xiang, A Xenocostas, M Karmazyn and Q Feng. (2009). Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1 α . *Stem Cells* 27:961–970.
 42. Aguirre A, JA Planell and E Engel. (2010). Dynamics of bone marrow-derived endothelial progenitor cell/mesenchymal stem cell interaction in co-culture and its implications in angiogenesis. *Biochem Biophys Res Commun* 400:284–291.
 43. Wang N, R Zhang, S-J Wang, C-L Zhang, L-B Mao, C-Y Zhuang, Y-Y Tang, X-G Luo, H Zhou and T-C Zhang. (2013). Vascular endothelial growth factor stimulates endothelial differentiation from mesenchymal stem cells via Rho/myocardin-related transcription factor-A signaling pathway. *Int J Biochem Cell Biol* 45:1447–1456.
 44. Blocki A, Y Wang, M Koch, P Peh, S Beyer, P Law, J Hui and M Raghunath. (2013). Not all MSCs can act as

- pericytes: functional *in vitro* assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis. *Stem Cells Dev* 22:2347–2355.
45. Chong JJ, H Reinecke, M Iwata, B Torok-Storb, A Stempien-Otero and CE Murry. (2013). Progenitor cells identified by PDGFR- α expression in the developing and diseased human heart. *Stem Cells Dev* 22:1932–1943.
 46. Schlosser S, C Dennler, R Schweizer, D Eberli, JV Stein, V Enzmann, P Giovanoli, D Erni and JA Plock. (2012). Paracrine effects of mesenchymal stem cells enhance vascular regeneration in ischemic murine skin. *Microvasc Res* 83:267–275.
 47. Lin RZ, R Moreno-Luna, B Zhou, WT Pu and JM Melero-Martin. (2012). Equal modulation of endothelial cell function by four distinct tissue-specific mesenchymal stem cells. *Angiogenesis* 15:443–455.
 48. Kalinina N, VY Syssoeva, K Rubina, YV Parfenova and V Tkachuk. (2011). Mesenchymal stem cells in tissue growth and repair. *Acta Nat* 3:30–37.
 49. Caplan AI. (2008). All MSCs are pericytes? *Cell Stem Cell* 3:229–230.
 50. Saleh FA, M Whyte, P Ashton and PG Genever. (2010). Regulation of mesenchymal stem cell activity by endothelial cells. *Stem Cells Dev* 20:391–403.
 51. Ball SG, AC Shuttleworth and CM Kielty. (2004). Direct cell contact influences bone marrow mesenchymal stem cell fate. *Int J Biochem Cell Biol* 36:714–727.
 52. Saleh FA, M Whyte and PG Genever. (2011). Effects of endothelial cells on human mesenchymal stem cell activity in a three-dimensional *in vitro* model. *Eur Cell Mater* 22:242–257.
 53. Pati S, MH Gerber, TD Menge, KA Wataha, Y Zhao, JA Baumgartner, J Zhao, PA Letourneau, MP Hubby, et al. (2011). Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. *PLoS One* 6:e25171.
 54. Pati S, AY Khakoo, J Zhao, F Jimenez, MH Gerber, M Harting, JB Redell, R Grill, Y Matsuo, et al. (2011). Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/ β -catenin signaling. *Stem Cells Dev* 20:89–101.
 55. Menge T, M Gerber, K Wataha, W Reid, S Guha, CS Cox, Jr., P Dash, MS Reitz, Jr., AY Khakoo and S Pati. (2013). Human mesenchymal stem cells inhibit endothelial proliferation and angiogenesis via cell-cell contact through modulation of the VE-Cadherin/ β -catenin signaling pathway. *Stem Cells Dev* 22:148–157.
 56. Stenman JM, J Rajagopal, TJ Carroll, M Ishibashi, J McMahon and AP McMahon. (2008). Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. *Science* 322:1247–1250.
 57. Dufourcq P, B Descamps, NF Tojais, L Leroux, P Oses, D Daret, C Moreau, J-MD Lamazière, T Couffinhal and C Dupl a. (2008). Secreted frizzled-related protein-1 enhances mesenchymal stem cell function in angiogenesis and contributes to neovessel maturation. *Stem Cells* 26:2991–3001.
 58. Alfaro MP, M Pagni, A Vincent, J Atkinson, MF Hill, J Cates, JM Davidson, J Rottman, E Lee and PP Young. (2008). The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. *Proc Natl Acad Sci U S A* 105:18366–18371.
 59. Duffy GP, S D'Arcy, T Ahsan, RM Nerem, T O'Brien and F Barry. (2010). Mesenchymal stem cells overexpressing ephrin-b2 rapidly adopt an early endothelial phenotype with simultaneous reduction of osteogenic potential. *Tissue Eng Part A* 16:2755–2768.
 60. Bidarra SJ, CC Barrias, MA Barbosa, R Soares, J Am ed e and PL Granja. (2011). Phenotypic and proliferative modulation of human mesenchymal stem cells via crosstalk with endothelial cells. *Stem Cell Res* 7:186–197.
 61. Sorrell JM, MA Baber and AI Caplan. (2009). Influence of adult mesenchymal stem cells on *in vitro* vascular formation. *Tissue Eng Part A* 15:1751–1761.
 62. Jimenez E, A Vicente, R Sacedon, JJ Munoz, G Weinmaster, AG Zapata and A Varas. (2001). Distinct mechanisms contribute to generate and change the CD4:CD8 cell ratio during thymus development: a role for the Notch ligand, Jagged1. *J Immunol* 166:5898–5908.
 63. Zacharek A, J Chen, X Cui, A Li, Y Li, C Roberts, Y Feng, Q Gao and M Chopp. (2007). Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. *J Cereb Blood Flow Metab* 27:1684–1691.
 64. Liu XB, J Jiang, C Gui, XY Hu, MX Xiang and JA Wang. (2008). Angiopoietin-1 protects mesenchymal stem cells against serum deprivation and hypoxia-induced apoptosis through the PI3K/Akt pathway. *Acta Pharmacol Sin* 29:815–822.
 65. Baraniak PR and TC McDevitt. (2010). Stem cell paracrine actions and tissue regeneration. *Regen Med* 5:121–143.
 66. Zhang H-C, X-B Liu, S Huang, X-Y Bi, H-X Wang, L-X Xie, Y-Q Wang, X-F Cao, J Lv and F-J Xiao. (2012). Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both *in vitro* and *in vivo*. *Stem Cells Dev* 21:3289–3297.
 67. Baglio SR, DM Pegtel and N Baldini. (2012). Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. *Front Physiol* 3:359.
 68. Kim H-S, D-Y Choi, SJ Yun, S-M Choi, JW Kang, JW Jung, D Hwang, KP Kim and D-W Kim. (2011). Proteomic analysis of microvesicles derived from human mesenchymal stem cells. *J Proteome Res* 11:839–849.
 69. Choi Y-A, J Lim, KM Kim, B Acharya, J-Y Cho, Y-C Bae, H-I Shin, S-Y Kim and EK Park. (2010). Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation. *J Proteome Res* 9:2946–2956.
 70. Xin H, Y Li, Y Cui, JJ Yang, ZG Zhang and M Chopp. (2013). Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. *J Cereb Blood Flow Metab* 33:1711–1715.
 71. Xin H, Y Li, Z Liu, X Wang, X Shang, Y Cui, Z Gang Zhang and M Chopp. (2013). Mir-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. *Stem Cells* [Epub ahead of print]; DOI: 10.1002/stem.1409.
 72. Lai RC, F Arslan, MM Lee, NS Sze, A Choo, TS Chen, M Salto-Tellez, L Timmers, CN Lee, et al. (2010). Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. *Stem Cell Res* 4:214–222.
 73. Zhu Y-G, X-M Feng, J Abbott, X-H Fang, Q Hao, A Monsel, J-M Qu, MA Matthay and JW Lee. (2013). Human mesenchymal stem cell microvesicles for treatment of *E. coli* endotoxin-induced acute lung injury in mice. *Stem Cells* [Epub ahead of print]; DOI: 10.1002/stem.1504.

74. Li T, Y Yan, B Wang, H Qian, X Zhang, L Shen, M Wang, Y Zhou, W Zhu, W Li and W Xu. (2013). Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev* 22:845–854.
75. Maumus M, C Jorgensen and D Noel. (2013). Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: Role of secretome and exosomes. *Biochimie* 95:2229–2234.
76. Katakowski M, B Buller, X Zheng, Y Lu, T Rogers, O Osobamiro, W Shu, F Jiang and M Chopp. (2013). Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. *Cancer Lett* 335:201–204.
77. Roccaro AM, A Sacco, P Maiso, AK Azab, YT Tai, M Reagan, F Azab, LM Flores, F Campigotto, et al. (2013). BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. *J Clin Invest* 123:1542–1555.
78. Kaigler D, PH Krebsbach, PJ Polverini and DJ Mooney. (2003). Role of vascular endothelial growth factor in bone marrow stromal cell modulation of endothelial cells. *Tissue Eng* 9:95–103.
79. Burlacu A, G Grigorescu, A-M Rosca, MB Preda and M Simionescu. (2012). Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis *in vitro*. *Stem Cells Dev* 22:643–653.
80. Findley CM, MJ Cudmore, A Ahmed and CD Kontos. (2007). VEGF induces Tie2 shedding via a phosphoinositide 3-Kinase/Akt-dependent pathway to modulate Tie2 signaling. *Arterioscler Thromb Vasc Biol* 27:2619–2626.
81. Leroux L, B Descamps, NF Tojais, B Séguy, P Oses, C Moreau, D Daret, Z Ivanovic, J-M Boiron and J-MD Lamazière. (2010). Hypoxia preconditioned mesenchymal stem cells improve vascular and skeletal muscle fiber regeneration after ischemia through a Wnt4-dependent pathway. *Mol Ther* 18:1545–1552.
82. Chang J, W Sonoyama, Z Wang, Q Jin, C Zhang, PH Krebsbach, W Giannobile, S Shi and C-Y Wang. (2007). Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. *J Biol Chem* 282:30938–30948.
83. Kasper G, JD Glaeser, S Geissler, A Ode, J Tuischer, G Matziolis, C Perka and GN Duda. (2007). Matrix metalloprotease activity is an essential link between mechanical stimulus and mesenchymal stem cell behavior. *Stem Cells* 25:1985–1994.
84. Ghajar CM, KS Blevins, CC Hughes, SC George and AJ Putnam. (2006). Mesenchymal stem cells enhance angiogenesis in mechanically viable prevascularized tissues via early matrix metalloproteinase upregulation. *Tissue Eng* 12:2875–2888.
85. Portalska KJ, A Leferink, N Groen, H Fernandes, L Moroni, C van Blitterswijk and J de Boer. (2012). Endothelial differentiation of mesenchymal stromal cells. *PLoS One* 7:e46842.
86. Nassiri SM, Z Khaki, M Soleimani, SH Ahmadi, I Jahanzad, S Rabbani, M Sahebjam, FA Ardalani and MS Fathollahi. (2007). The similar effect of transplantation of marrow-derived mesenchymal stem cells with or without prior differentiation induction in experimental myocardial infarction. *J Biomed Sci* 14:745–755.
87. Vittorio O, E Jacchetti, S Pacini and M Cecchini. (2013). Endothelial differentiation of mesenchymal stromal cells: when traditional biology meets mechanotransduction. *Integr Biol* 5:291–299.
88. Lionetti V, M Cecchini and C Ventura. (2010). Nanomechanics to drive stem cells in injured tissues: insights from current research and future perspectives. *Stem Cells Dev* 20:561–568.
89. Portalska KJ, A Leferink, N Groen, H Fernandes, L Moroni, C van Blitterswijk and J de Boer. (2012). Endothelial differentiation of mesenchymal stromal cells. *PLoS One* 7:e46842.
90. König J, B Huppertz, G Desoye, O Parolini, JD Fröhlich, G Weiss, G Dohr, P Sedlmayr and I Lang. (2011). Amnion-derived mesenchymal stromal cells show angiogenic properties but resist differentiation into mature endothelial cells. *Stem Cells Dev* 21:1309–1320.
91. Davani S, A Marandin, N Mersin, B Royer, B Kantelip, P Hervé, J-P Etievend and J-P Kantelip. (2003). Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. *Circulation* 108:II-253–II-258.
92. Lee M-Y, J-P Huang, Y-Y Chen, JD Aplin, Y-H Wu, C-Y Chen, P-C Chen and C-P Chen. (2009). Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin $\alpha_5\beta_1$. *PLoS One* 4:e6913.
93. Mayer H, H Bertram, W Lindenmaier, T Korff, H Weber and H Weich. (2005). Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: Autocrine and paracrine role on osteoblastic and endothelial differentiation. *J Cell Biochem* 95:827–839.
94. Qiu X, C Sun, W Yu, H Lin, Z Sun, Y Chen, R Wang and Y Dai. (2012). Combined strategy of mesenchymal stem cell injection with vascular endothelial growth factor gene therapy for the treatment of diabetes-associated erectile dysfunction. *J Androl* 33:37–44.
95. Shabbir A, D Zisa, G Suzuki and T Lee. (2009). Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. *Am J Physiol Heart Circ Physiol* 296:H1888–H1897.
96. Barker TH. (2011). The role of ECM proteins and protein fragments in guiding cell behavior in regenerative medicine. *Biomaterials* 32:4211–4214.
97. Wu C-C, Y-C Chao, C-N Chen, S Chien, Y-C Chen, C-C Chien, J-J Chiu, B Linju Yen. (2008). Synergism of biochemical and mechanical stimuli in the differentiation of human placenta-derived multipotent cells into endothelial cells. *J Biomech* 41:813–821.
98. Au P, J Tam, D Fukumura and RK Jain. (2008). Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. *Blood* 111:4551–4558.
99. Carrion B, CP Huang, CM Ghajar, S Kachgal, E Kniazeva, NL Jeon and AJ Putnam. (2010). Recreating the perivascular niche *ex vivo* using a microfluidic approach. *Biotechnol Bioeng* 107:1020–1028.
100. Zhou J, M Cheng, Y-H Liao, Y Hu, M Wu, Q Wang, B Qin, H Wang, Y Zhu, et al. (2013). Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells. *PLoS One* 8:e63126.
101. Ohtani K, GJ Vlachojannis, M Koyanagi, J-N Boeckel, C Urbich, R Farcas, H Bonig, VE Marquez, AM Zeiher and S Dimmeler. (2011). Epigenetic regulation of endothelial lineage committed genes in pro-Angiogenic hematopoietic and endothelial progenitor cells. *Circ Res* 109:1219–1229.
102. Gomes SA, EB Rangel, C Premer, RA Dulce, Y Cao, V Florea, W Balkan, CO Rodrigues, AV Schally and JM Hare. (2013). S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. *Proc Natl Acad Sci U S A* 110:2834–2839.

103. Ahmed RPH, KH Haider, J Shujia, MR Afzal and M Ashraf. (2010). Sonic hedgehog gene delivery to the rodent heart promotes angiogenesis via iNOS/Netrin-1/PKC pathway. *PLoS One* 5:e8576.
104. Ocarino NM, JN Boeloni, AM Goes, JF Silva, U Marubayashi and R Serakides. (2008). Osteogenic differentiation of mesenchymal stem cells from osteopenic rats subjected to physical activity with and without nitric oxide synthase inhibition. *Nitric Oxide* 19:320–325.
105. Birmingham E, G Niebur, P McHugh, G Shaw, F Barry and L McNamara. (2012). Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. *Eur Cell Mater* 23:13–27.
106. Tasso R, V Ulivi, D Reverberi, C Lo Sicco, F Descalzi and R Cancedda. (2013). *In vivo* implanted bone marrow-derived mesenchymal stem cells trigger a cascade of cellular events leading to the formation of an ectopic bone regenerative niche. *Stem Cells Dev* [Epub ahead of print]; DOI:10.1089/scd.2013.0313.
107. Kurpinski K, H Lam, J Chu, A Wang, A Kim, E Tsay, S Agrawal, DV Schaffer and S Li. (2010). Transforming growth factor- β and notch signaling mediate stem cell differentiation into smooth muscle cells. *Stem Cells* 28:734–742.
108. Boopathy AV, KD Pendergrass, PL Che, Y-S Yoon and ME Davis. (2013). Oxidative stress-induced Notch1 signaling promotes cardiogenic gene expression in mesenchymal stem cells. *Stem Cell Res Ther* 4:43.
109. Lee RH, N Yoon, JC Reneau and DJ Prockop. (2012). Pre-activation of human MSCs with TNF- α enhances tumor-suppressive activity. *Cell Stem Cell* 11:825–835.
110. Secchiero P, S Zorzet, C Tripodo, F Corallini, E Melloni, L Caruso, R Bosco, S Ingraio, B Zavan and G Zauli. (2010). Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. *PLoS One* 5:e11140.
111. Gomes CM. (2013). The dual role of mesenchymal stem cells in tumor progression. *Stem Cell Res Ther* 4:42.
112. Dvorak HF. (2003). How tumors make bad blood vessels and stroma. *Am J Pathol* 162:1747–1757.
113. Zhang Z, KG Neiva, MW Lingen, LM Ellis and JE Nör. (2009). VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. *Cell Death Differ* 17:499–512.
114. Kerbel RS. (2008). Tumor angiogenesis. *N Engl J Med* 358:2039–2049.
115. Wels J, RN Kaplan, S Rafii and D Lyden. (2008). Migratory neighbors and distant invaders: tumor-associated niche cells. *Genes Dev* 22:559–574.
116. Ding W, TR Knox, RC Tschumper, W Wu, SM Schwager, JC Boysen, DF Jelinek and NE Kay. (2010). Platelet-derived growth factor (PDGF)–PDGF receptor interaction activates bone marrow–derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. *Blood* 116:2984–2993.
117. Menon LG, S Picinich, R Koneru, H Gao, SY Lin, M Koneru, P Mayer-Kuckuk, J Glod and D Banerjee. (2007). Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. *Stem Cells* 25:520–528.
118. Huang W, M Chang, K Tsai, M Hung, H Chen and S Hung. (2012). Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. *Oncogene* 32:4343–4345.
119. Burns JS, M Kristiansen, LP Kristensen, KH Larsen, MO Nielsen, H Christiansen, J Nehlin, JS Andersen and M Kassem. (2011). Decellularized matrix from tumorigenic human mesenchymal stem cells promotes neovascularization with galectin-1 dependent endothelial interaction. *PLoS One* 6:e21888.
120. Zhang T, YW Lee, YF Rui, TY Cheng, XH Jiang and G Li. (2013). Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. *Stem Cell Res Ther* 4:70.
121. Proulx-Bonneau S, A Guezguez and B Annabi. (2011). A concerted HIF-1 α /MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells. *PLoS One* 6:e21511.
122. Wang X, Z Zhang and C Yao. (2010). Angiogenic activity of mesenchymal stem cells in multiple myeloma. *Cancer Invest* 29:37–41.
123. Fouraschen SM, Q Pan, PE de Ruitter, WR Farid, G Kazemier, J Kwekkeboom, JN Ijzermans, HJ Metselaar, HW Tilanus and J de Jonge. (2012). Secreted factors of human liver-derived mesenchymal stem cells promote liver regeneration early after partial hepatectomy. *Stem Cells Dev* 21:2410–2419.
124. Gruber R, B Kandler, P Holzmann, M Vögele-Kadletz, U Losert, MB Fischer and G Watzek. (2005). Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. *Tissue Eng* 11:896–903.
125. Annabi B, E Naud, Y-T Lee, N Eliopoulos and J Galipeau. (2004). Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. *J Cell Biochem* 91:1146–1158.
126. Sun B, S Zhang, C Ni, D Zhang, Y Liu, W Zhang, X Zhao, C Zhao and M Shi. (2005). Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. *Stem Cells Dev* 14:292–298.
127. Suzuki K, R Sun, M Origuchi, M Kanehira, T Takahata, J Itoh, A Umezawa, H Kijima, S Fukuda and Y Saijo. (2011). Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. *Mol Med* 17:579–587.
128. Liu Y, ZP Han, SS Zhang, YY Jing, XX Bu, CY Wang, K Sun, GC Jiang, X Zhao, et al. (2011). Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. *J Biol Chem* 286:25007–25015.
129. Zhu W, L Huang, Y Li, X Zhang, J Gu, Y Yan, X Xu, M Wang, H Qian and W Xu. (2012). Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth *in vivo*. *Cancer Lett* 315:28–37.
130. Zhu W, L Huang, Y Li, H Qian, X Shan, Y Yan, F Mao, X Wu and W-R Xu. (2011). Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth. *Cell Cycle* 10:3198–3207.
131. Quante M, S Tu, H Tomita, T Gonda, S Wang, S Takashi, G Baik, W Shibata, B Diprete, et al. (2011). Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. *Cancer Cell* 19:257–272.
132. Mi Z, SD Bhattacharya, VM Kim, H Guo, LJ Talbot and PC Kuo. (2011). Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. *Carcinogenesis* 32:477–487.

133. Stagg J. (2008). Mesenchymal Stem Cells in Cancer. *Stem Cell Rev* 4:119–124.
134. Paunescu V, FM Bojin, CA Tatu, OI Gavriliuc, A Rosca, AT Gruia, G Tanasie, C Bunu, D Crisnic, et al. (2011). Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. *J Cell Mol Med* 15:635–646.
135. Calabrese C, H Poppleton, M Kocak, TL Hogg, C Fuller, B Hamner, EY Oh, MW Gaber, D Finklestein and M Allen. (2007). A perivascular niche for brain tumor stem cells. *Cancer Cell* 11:69–82.
136. Charles N, T Ozawa, M Squatrito, A-M Bleau, CW Brennan, D Hambardzumyan and EC Holland. (2010). Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. *Cell Stem Cell* 6:141–152.
137. Borovski T, E De Sousa, F Melo, L Vermeulen and JP Medema. (2011). Cancer stem cell niche: the place to be. *Cancer Res* 71:634–639.
138. Orimo A, PB Gupta, DC Sgroi, F Arenzana-Seisdedos, T Delaunay, R Naeem, VJ Carey, AL Richardson and RA Weinberg. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell* 121:335–348.
139. Bagley RG, W Weber, C Rouleau, M Yao, N Honma, S Kataoka, I Ishida, BL Roberts and BA Teicher. (2009). Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. *Int J Oncol* 34:619–627.
140. Kucerova L and S Skolekova. (2013). Tumor microenvironment and the role of mesenchymal stromal cells. *Neoplasma* 60:1–10.
141. Shinagawa K, Y Kitadai, M Tanaka, T Sumida, M Onoyama, M Ohnishi, E Ohara, Y Higashi, S Tanaka, W Yasui and K Chayama. (2013). Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. *Int J Cancer* 132:813–823.
142. Potenta S, E Zeisberg and R Kalluri. (2008). The role of endothelial-to-mesenchymal transition in cancer progression. *Br J Cancer* 99:1375–1379.
143. Ghaedi M, M Soleimani, NM Taghvaei, M Sheikhatollahi, K Azadmanesh, AS Lotfi and J Wu. (2011). Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. *J Gene Med* 13:171–180.
144. Klopp AH, A Gupta, E Spaeth, M Andreeff and F Marini. (2011). Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? *Stem Cells* 29:11–19.
145. Ramasamy R, EW Lam, I Soeiro, V Tisato, D Bonnet and F Dazzi. (2007). Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on *in vivo* tumor growth. *Leukemia* 21:304–310.
146. Villars F, B Guillotin, T Amedee, S Dutoya, L Bordenave, R Bareille and J Amedee. (2002). Effect of HUVEC on human osteoprogenitor cell differentiation needs heterotypic gap junction communication. *Am J Physiol Cell Physiol* 282:C775–C785.

Address correspondence to:
 Dr. Seyed Mahdi Nassiri
 Department of Clinical Pathology
 Faculty of Veterinary Medicine
 University of Tehran
 Qareeb Street
 Azadi Avenue
 P.O Box: 14155-6453
 Tehran 1419963111
 Iran

E-mail: nasirim@ut.ac.ir; nasirim@vetmed.ut.ac.ir

Received for publication August 31, 2013

Accepted after revision October 28, 2013

Prepublished on Liebert Instant Online October 30, 2013

This article has been cited by:

1. Reza Rahbarghazi, Seyed Mahdi Nassiri, Seyed Hossein Ahmadi, Elham Mohammadi, Shahram Rabbani, Atefeh Araghi, Hossein Hosseinkhani. 2014. Dynamic induction of pro-angiogenic milieu after transplantation of marrow-derived mesenchymal stem cells in experimental myocardial infarction. *International Journal of Cardiology* . [[CrossRef](#)]